Ciudad de la Habana, Cuba

Karina García Martínez


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Karina García Martínez

Introduction

Karina García Martínez is a renowned inventor based in Ciudad de la Habana, Cuba. With a keen focus on immunology, she has made significant contributions to the field of cancer therapeutics through her innovative research and development of novel polypeptides.

Latest Patents

Karina holds a patent for her invention titled "Immunomodulatory interleukin-2 polypeptides and methods of treating melanoma." This groundbreaking patent details polypeptides that exhibit a high sequence homology with human interleukin-2 (IL-2), featuring specific mutations that enhance their immunomodulatory effects. The polypeptides specifically target and preferentially impact regulatory T cells, thereby offering potential therapeutic benefits in treating melanoma and other chronic infectious diseases. The invention also includes various pharmaceutical compositions that incorporate these polypeptides.

Career Highlights

Karina García Martínez currently works at the prestigious Centro de Inmunología Molecular, where she has been instrumental in advancing research related to immunology and cancer treatment. Her dedication to science and her innovative approach have positioned her as a leading figure in her field. With one active patent to her name, she exemplifies the spirit of innovation that drives research institutions forward.

Collaborations

Throughout her career, Karina has worked closely with talented colleagues, including Kalet León Monzón and Tania Carmenate Portilla. Their collaboration has fostered an environment of innovation and discovery, allowing them to explore the vast potential of immunomodulatory therapies.

Conclusion

Karina García Martínez is an exemplary inventor whose work has the potential to shape the future of cancer treatment. Her innovative polypeptides and the associated therapeutic methods highlight the importance of research in addressing complex health challenges. As she continues her work at the Centro de Inmunología Molecular, her contributions will undoubtedly leave a lasting impact on both the scientific community and patients battling melanoma and other immune-related diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…